Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, First-in-Human Study to Evaluate CANNABICS RCC-33

Trial Profile

A Phase 1/2a, First-in-Human Study to Evaluate CANNABICS RCC-33

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RCC-33 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors CNBX Pharmaceuticals
  • Most Recent Events

    • 31 May 2022 According to a CNBX Pharmaceuticals media release, this study is expected to be launched by end of 2023.
    • 21 Oct 2021 EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel.The publication details Company plans for Phase I/II clinical studies for RCC-33.
    • 17 Mar 2021 According to a Cannabics Pharmaceuticals media release, the company is aiming to schedule a pre-IND meeting with the US Food and Drug Administration by next quarter and start this study by the beginning of 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top